The drug discovery, development, and analytical service provider has opened a new facility in Sandwich, UK to support the development and manufacturing of APIs – a market expected to top $270bn by 2026.
Using its proprietary bioprocessing technology, Cellesce is scaling the production of breast organoids for drug discovery research – with plans to expand into other areas of unmet medical need, says CEO.
The clinical informatics company Ovation.io secures $5m in Series A funding to expand its platform designed to help diagnostic labs become a “keystone of precision medicine in their community,” says CEO.
Elpis Biomed is scaling its proprietary ‘direct cellular reprogramming platform’ – and has its sights set on becoming a global provider of high-quality human cells, with strategic partnerships soon to be announced, says the company’s founder.
Researchers are using artificial intelligence to catalyze drug discovery and preclinical drug development - improving predictive models to guide efficient design and optimizing multi-drug regimens, as two recent examples.